Trial reportJournal of gastroenterology2015
Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.
Trial report in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.The Cochrane database of systematic reviews · 2018Pooled it
- Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.BMC gastroenterology · 2020Trial
- Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.Journal of gastroenterology · 2017Trial
- Importance of early use of tolvaptan in hyponatremic acutely decompensated heart failure patients, a retrospective study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Transferrin-binding domain inserted-adenovirus hexon engineering enables systemic immune evasion and intratumoral T-cell activation.Theranostics · 2025Article
- Tolvaptan and the role of kidney aquaporin-2 abundance in managing volume overload in patients with CKD.Clinical kidney journal · 2024Article
- Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.Journal of gastroenterology · 2021Article
- Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.Journal of gastroenterology · 2020Article
- Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.International urology and nephrology · 2019Article
- Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.Clinical drug investigation · 2019Article
- Impact of continued administration of tolvaptan on cirrhotic patients with ascites.BMC pharmacology & toxicology · 2018Observational
- Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.Heart and vessels · 2018Article
- Response criteria of tolvaptan for the treatment of hepatic edema.Journal of gastroenterology · 2018Article
- Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.Biomedical reports · 2017Article
- Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.Journal of clinical biochemistry and nutrition · 2017Article
- Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.Clinical drug investigation · 2016Article
- Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.World journal of gastroenterology · 2016Article
- Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?World journal of gastroenterology · 2015Review
- Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.Biomedical reports · 2015Article
- Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.Internal medicine (Tokyo, Japan)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hypoalbuminemia often fail to respond to increased doses of loop diuretics. We therefore performed a post hoc analysis to investigate the pharmacological action of tolvaptan and whether it is dependent on the serum albumin level.
methodsThis analysis was based on four previous clinical trials of tolvaptan in patients with liver cirrhosis who exhibited insufficient response to conventional diuretics. We analyzed the correlation between the change in the initial 24-h cumulative urine volume from baseline and the serum albumin level at baseline, and assessed potential predictive factors of response to tolvaptan.
resultsThe correlation coefficient was 0.029 in the placebo group and -0.112 in the 7.5 mg tolvaptan group of patients with liver cirrhosis. Administration of tolvaptan provoked a stable response regardless of the serum albumin level. Tolvaptan use was identified as a significant predictor of pharmacological action, and was shown to change the initial urine volume by 885 mL (P < 0.0001) in liver cirrhosis patients.
conclusionsIn this post hoc analysis, tolvaptan increased the initial urine volume from baseline regardless of serum albumin levels. Use of tolvaptan as an add-on therapy to loop diuretics can be considered an optimal therapeutic option in patients with insufficient response to loop diuretics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.